Oral ComplicationNCT06918327
Effect of CGF on Postoperative Pain After Third Molar Surgery
A study testing Concentrated Growth Factor and non-CGF in people with Oral Complication, run by Ege University at 1 site in Turkey (Türkiye).
Trial summary
The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Oral Complication
- What is being tested?
- Concentrated Growth Factor and non-CGF
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 49 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 May 2017to 5 Jun 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
- Patients without any systemic disease
- Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.
Who cannot join
- Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
- Having a systemic viral, fungal or bacterial infection
- Patients with acute or chronic maxillary sinusitis
- Suspected or diagnosed pregnancy and nursing mothers
- Patients with heart and vascular diseases
- Patients with liver disease, haematological disease and neoplastic disease
Show all 12Show fewer
- Patients who have recently received anti-inflammatory therapy
- Patients with chronic medication use (antihistamines, NSAIDs, steroids and antidepressants)
- Patients predisposed to psychotic or psychopathic tendencies
- Patients with rheumatic diseases, blood diseases, diabetes mellitus
- Patients at cardiological risk of infective endocarditis
- Patients under antibiotic pressure
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ege University Faculty of Dentistry
Izmir, Bornova, 35040
About this study
Official title: The Power of Concentrated Growth Factor: A New Era in Pain Management in Third Molar Surgery
The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.
The main question it aims to answer is:
Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).
- Conditions
- Oral Complication
- Being tested
- Concentrated Growth Factor, non-CGF
- Keywords
- Pain, Third molar, VAS scale
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Concentrated Growth FactorOther
Bilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets.
non-CGFOther
The other extraction socket is left empty for control purposes.
| Study group | Role | What they receive |
|---|---|---|
| CGF | Experimental | Participants received CGF after the operation on one side Receives: Other: Concentrated Growth Factor; Other: non-CGF |
| non-CGF | No intervention | The other extraction socket is left empty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery
The primary outcome measure is postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale (VAS). Patients are asked to mark the pain they felt on the scale (10 cm long line) on the (1-7) days after the operation. The end of the line indicates unbearable pain, the beginning indicates no pain.
Measured: The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2025
- Study start1 May 2017
- Primary completion1 Jan 2018
- Study completion5 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral ComplicationStudies of the same condition, open and under way.
- More trials run by Ege UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ege University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mert Zeytinoğlu, Ege University
- Investigators
- Mert Zeytinoğlu, Principal investigator, Ege University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06918327
- Sponsor's protocol ID
- EGE-DHF-MZ-002
- Status last verified
- Mar 2025
- First submitted
- 31 Mar 2025
- Last updated
- 20 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Power of Concentrated Growth Factor: A New Era in Pain Management in Third Molar Surgery
- ClinicalTrials.gov ID
- NCT06918327
- Acronym / sponsor ID
- EGE-DHF-MZ-002
- Conditions
- Oral Complication
- Keywords
- Pain, Third molar, VAS scale
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- Ege UniversityUniversity, hospital or other
- Study start
- 1 May 2017 (actual)
- Primary completion
- 1 Jan 2018 (actual)
- Study completion
- 5 Jun 2018 (actual)
- First posted
- 9 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.
The main question it aims to answer is:
Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CGF | Experimental | Other: Concentrated Growth Factor, Other: non-CGFParticipants received CGF after the operation on one side |
| non-CGF | No intervention | –The other extraction socket is left empty |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
- Patients without any systemic disease
- Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.
Key exclusion criteria (12 listed)
- Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
- Having a systemic viral, fungal or bacterial infection
- Patients with acute or chronic maxillary sinusitis
- Suspected or diagnosed pregnancy and nursing mothers
- Patients with heart and vascular diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Concentrated Growth FactorBilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets. | Other | CGF |
| non-CGFThe other extraction socket is left empty for control purposes. | Other | CGF |
Primary outcome
Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery
Time frame: The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).
The primary outcome measure is postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale (VAS). Patients are asked to mark the pain they felt on the scale (10 cm long line) on the (1-7) days after the operation. The end of the line indicates unbearable pain, the beginning indicates no pain.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Oral Complication
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
RecruitingPhase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mert Zeytinoğlu principal investigator
Ege University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Concentrated Growth Factor and non-CGF in people with Oral Complication, run by Ege University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery (time frame: The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2025.